ProMIS Neurosciences
PMN

$1.23

0.81%

Market Cap: $36.8M

About: ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Employees: 7

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 16 [Q1] → 16 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0.7% less ownership

Funds ownership: 17.91% [Q1] → 17.21% (-0.7%) [Q2]

24% less capital invested

Capital invested by funds: $6.46M [Q1] → $4.9M (-$1.56M) [Q2]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for PMN.

See Analyst Rankings

Financial journalist opinion

ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that preclinical data supporting the potential role of its lead product candidate, PMN310, as a treatment for AD will be highlighted in an oral presentation at the 4th International Conference on Cognitive & Behavioral Neurosciences (ICBN) taking place from September 12-13, 2024 in Lisbon, Portugal.

ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 05, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate at the H.C. Wainwright 26th Annual Global Investment Conference and will conduct one-on-one meetings from September 9 – 10, 2024.

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that Neil Warma, interim Chief Executive Officer of ProMIS Neurosciences and Larry Altstiel, M.D., Ph.D., Chief Medical Officer of ProMIS Neurosciences, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 6, 2024 at 12:00 p.m. ET.

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

Preclinical data showed strong antibody responses with no measurable pro-inflammatory T cell responses against AßO and support novel approach for potential Alzheimer's disease vaccine

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospinal fluid (CSF) suggestive of its potential for target engagement in Alzheimer's disease patients

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the warrants subject to shareholder approval

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer's disease on track for mid-2024 Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer's disease on track for mid-2024

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

Study results support ProMIS' TDP-43 misfolding-specific epitope as a potential therapeutic target for Amyotrophic Lateral Sclerosis (ALS) Study results support ProMIS' TDP-43 misfolding-specific epitope as a potential therapeutic target for Amyotrophic Lateral Sclerosis (ALS)

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 04, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that company management will participate in three upcoming investor conferences:

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

See News Rankings